Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the immunogenicity and safety of a live attenuated mumps vaccine in healthy infants between 8 - 18 months old with a commercialized live attenuated mumps vaccine as the control vaccine.

Detailed Description
-----------------
This study is a randomized, blind, single-center, controlled phase III clinical trial. The purpose of this study is to evaluate the immunogenicity and safety of a live attenuated mumps vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. The control vaccine is a commercialized live attenuated mumps vaccine manufactured by ZheJiang VACN bio-pharmaceutical Co. Ltd. All participants are healthy infants between 8 - 18 months old, and will be randomly assigned into experimental group or control group in the ratio 1:1.

Official Title
-----------------
A Blind, Randomized and Controlled Clinical Trial With Live Attenuated Mumps Vaccines in Healthy Infants

Conditions
-----------------
Mumps

Intervention / Treatment
-----------------
* Biological: Investigational live attenuated mumps vaccine
* Biological: control live attenuated mumps vaccine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy volunteer between 8 - 18 months old; Proven legal identity; Guardian(s) of the volunteer should be capable of understanding the written consent form, and such form should be signed before the infant being included into this study; Complying with the requirement of the study protocol; Exclusion Criteria: Axillaty temperature > 37.0 °C; Any significant abnormity of heart, lung, liver, spleen, lymph nodes, or pharynx; Acute disease or acute stage of chronic disease within 7 days prior to study entry; Prior vaccination with mumps vaccine or with history of mumps infection; History of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) to vaccination, such as urticaria, difficulty in breathing, angioneurotic edema, abdominal pain, etc; Receipt of any of the following products: Any subunit vaccine or inactivated vaccine within 14 days prior to study entry; Any live attenuated vaccine within 28 days prior to study entry; Any other investigational medicine(s) within 30 days prior to study entry; Blood product (e.g., immunoglobulin) within 3 months prior to study entry; Any immunosuppressant, cytotoxic medicine, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) within 6 month prior to study entry; Epilepsy (except febrile seizures), history of seizures or convulsions, or a family history of mental illness; Autoimmune disease or immunodeficiency; Congenital malformation, developmental disorders, or serious chronic diseases (e.g., Down's syndrome, diabetes, sickle cell anemia or neurological disorders); Severe malnutrition; Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities); Any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators; Participants with the following conditions between day 0 - 28 of this study would be included in the full analysis set (FAS), but would be excluded from the per protocol set (PPS): Receipt of any other investigational or unregistered product (drug or vaccine); Receipt of immunosuppressant (dosage of corticosteroid ≥ that in 0.5 mg prednisone per kg weight per day) for > 14 days consecutively, except for inhalant or locally administrated corticosteroid; Receipt of immunoglobulin and/or other blood product; Newly diagnosed autoimmune disease or immunodeficiency (e.g., HIV infection);

Ages Eligible for Study
-----------------
Minimum Age: 8 Months
Maximum Age: 18 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Experimental Group<br>Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0; Intervention: investigational live attenuated mumps vaccine; | Biological: Investigational live attenuated mumps vaccine<br>* The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.<br>|
| Active Comparator: Control Group<br>Single intramuscular injection of the control vaccine (0.5 ml) on Day 0; Intervention: control live attenuated mumps vaccine; | Biological: control live attenuated mumps vaccine<br>* The control vaccine was manufactured by Zhejiang VACN bio-pharmaceutical Co. Ltd.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The seroconversion rates (SCRs) of susceptible subjects in each group | Subjects whose pre-immune HI antibody level < 1:2 are considered susceptible; among these subjects, those with post-immune HI antibody level ≥ 1:2 are considered seroconverted. | 28 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The incidences of adverse events (AEs) of each group | AEs occurred within 28 days after injection will be collected. | 28 days | 
| The incidences of serious adverse events (SAEs) of each group | SAEs occurred within 28 days after injection will be collected. | 28 days | 
| The post-immune geometric mean titers (GMTs) of susceptible subjects in each group | Subjects whose pre-immune HI antibody level < 1:2 are considered susceptible. | 28 days | 
| The overall SCRs of each group | Subjects whose pre-immune HI antibody level < 1:2 and post-immune antibody level ≥ 1:2, or those whose pre-immune antibody level ≥ 1:2 and the increase of post-immune HI antibody level ≥ 4 folds are considered seroconverted. | 28 days | 
| The overall post-immune GMTs of each group | The GMTs of all the subjects in each group. | 28 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
safety, live attenuated mumps vaccine, immunogenicity, infant